Abstract
CD34-positive cells were isolated from cord blood (n = 8), bone marrow (n = 4) and leukapheresed material (n = 7), using an immunomagnetic isolation technique, MACS (Miltenyi Biotec, Bergisch Gladbach, Germany). In flow cytometric analysis, cell populations after enrichment revealed a fraction of 96.1% (cord blood), 96.2% (bone marrow) and 98.6% (leukapheresis material) CD34-positive cells. Cells were further stained with antibodies specific for CD44 isoforms: CD44s (SFF-2), CD44v5 (VFF-8) and CD44v6 (VFF-18). CD44-positive cells were detected by directly (FITC, fluorescein isothiocyanate) or indirectly (streptavidin-PE, phycoerythrin)-conjugated fluorochromes in flow cytometric analysis. Analysis was restricted to CD34-positive cells. A high expression of CD44s was noted in all kinds of material under investigation with mean values in the range of 98.6–100%. There was little expression of CD44v6 (mean values in the range of 1.5–3.6%) and very slight expression of CD44v5 (mean values in the range of 0.6–1.4%). The finding that CD34-positive hematopoietic stem cells express CD44v5 and CD44v6 to a very small extent offers the possibility of using antibodies specific to CD44v5 and CD44v6 in immunopurging in the course of autologous stem cell transplantation.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Neu, S., Geiselhart, A., Sproll, M. et al. Expression of CD44 isoforms by highly enriched CD34-positive cells in cord blood, bone marrow and leukaphereses. Bone Marrow Transplant 20, 593–598 (1997). https://doi.org/10.1038/sj.bmt.1700940
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1700940
Keywords
This article is cited by
-
Novel CAR T therapy is a ray of hope in the treatment of seriously ill AML patients
Stem Cell Research & Therapy (2021)
-
T-cell-based immunotherapy of acute myeloid leukemia: current concepts and future developments
Leukemia (2021)
-
Cell-based immunotherapy approaches for multiple myeloma
British Journal of Cancer (2019)
-
Transcriptomics of the late gestation ovine fetal brain: modeling the co-expression of immune marker genes
BMC Genomics (2014)
-
Growth advantage of chronic myeloid leukemia CFU-GM in vitro : survival to growth factor deprivation, possibly related to autocrine stimulation, is a more common feature than hypersensitivity to GM-CSF/IL3 and is efficiently counteracted by retinoids ± α-interferon
Leukemia (2001)